Evidence map›Paper›PMID 31098421›Full record

ArticleInvestigative and clinical urology2019

Sung Han Kim, Weon Seo Park, Jinsoo Chung

Open access · diamondAbstract read
In one paragraph

Article in Investigative and clinical urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. [Clinicopathological and molecular features of acquired cystic kidney disease and associated renal cell carcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Article
  2. Article
  3. [Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Sung Han KimDepartment of Urology, Center for Prostate Cancer, Research Institute and National Cancer Center, Goyang, Korea.
Weon Seo ParkDepartment of Pathology, Center for Prostate Cancer, Research Institute and National Cancer Center, Goyang, Korea.
Jinsoo ChungDepartment of Urology, Center for Prostate Cancer, Research Institute and National Cancer Center, Goyang, Korea.ORCID 0000-0003-2251-5331
National Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Multilocular cystic renal neoplasm of low malignant potential (MCRNLMP) and clear cell renal cell carcinoma with cystic change (MCRCC) have different prognoses despite similar histologic characteristics. The aim of this study was to identify differentially mutated genes in resected tumor specimens from patients diagnosed with MCRNLMP and MCRCC using a kidney cancer gene panel. Materials and Methods: Between 2009 and 2016, 13 MCRNLMP and 17 MCRCC cases were selected. Tumor tissues from 5 MCRNLMP and 16 MCRCC cases were subjected to gene sequencing to detect mutations among 88 genes selected from a kidney cancer gene panel after quality control. Fisher's exact test was used to compare gene mutation profiles between the two diseases. Genes were considered to be positive for mutation according to the presence of an in-frame/frameshift deletion or insertion, missense/nonsense mutation, or multi-hit mutation. Results: During a median follow-up period of 66.2 months, there was only one case of MCRCC recurrence among all 30 patients. Target gene sequencing showed that 35 genes tended to be more frequently positive in either disease group, with six genes showing a significantly different frequency of mutation between the groups: Conclusions: Six candidate genes showed significantly different mutation patterns between MCRNLMP and MCRCC, providing insight into their pathogenic mechanisms and differential prognoses.

Indexed as

MutationAdultAgedAged, 80 and overCarcinoma, Renal CellCarrier ProteinsDiagnosis, DifferentialDNA-Binding ProteinsFemaleHistone-Lysine N-MethyltransferaseHumansKidney Diseases, CysticKidney NeoplasmsMaleMiddle AgedProto-Oncogene Proteins c-bcrBCR protein, humanCarrier ProteinsDNA-Binding ProteinsFGFR3 protein, humanGIGYF2 protein, humanHistone-Lysine N-MethyltransferaseKMT2C protein, humanProto-Oncogene Proteins c-bcrReceptor, Fibroblast Growth Factor, Type 3SETD2 protein, humanTSC2 protein, humanTuberous Sclerosis Complex 2 ProteinCarcinoma, renal cellCystsGenesTargeted mutationTissues

Identifiers

PMID31098421
PMCPMC6495037
OpenAlexW2942830814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.